Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES CABERGOLINE TABLETS
Authorized Generic of DOSTINEX (cabergoline tablets)

PEAPACK, NJ, September 2014 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE), is pleased to announce the introduction of cabergoline tablets to its ever-expanding generic pharmaceutical product line. The product is offered in tablet form in dosage strengths of 0.5 mg x eight tablets per bottle.

Greenstone’s cabergoline tablets product is the authorized generic of, and equivalent to the innovator’s product, DOSTINEX (cabergoline tablets). This new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., one of the world’s premiere biopharmaceutical companies. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients it serves.

See the Full Prescribing Information for Greenstone’s cabergoline tablets at http://www.greenstonellc.com/product-list.aspx. For more information about Greenstone LLC and its products, visit http://greenstonellc.com.